Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia
Not yet recruiting · NCT07315373 · Registry updated 2026-01-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Optimal Dose of Zanubrutinib to Treat Adult Immune Thrombocytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 1 | 2026-01-02 | NCT07315373 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University People's Hospital | 269 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||